{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T04:24:18Z","timestamp":1770611058462,"version":"3.49.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2043,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Department of Clinical Sciences at Auburn University College of Veterinary Medicine"},{"name":"Department of Clinical Sciences at Auburn University College of Veterinary Medicine"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prolonged cytotoxic concentrations of cytarabine (CA) are required for maximum cytotoxicity. DepoCyt is a human liposomal cytarabine (LC) product that lasts longer in plasma and CSF compared with free CA (FC). The use of LC has not been evaluated in dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To perform a LC pharmacokinetic (PK) study when administered SC in dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Five healthy female beagles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Three-period, 3-treatment, nonblinded, randomized, and crossover design, including a pilot study. LC was administered at 50\u2009mg\/m2 SC and FC was administered at 25 and 50\u2009mg\/m2 SC and IV. Plasma CA concentrations were measured until 240, 72, and 8 hours after SC LC, SC FC, and IV FC administration, respectively. CA plasma concentrations were quantitated by ultra-high-performance liquid chromatography with mass spectrometry (MS\/MS) detection and concentration-time profiles were evaluated by noncompartmental analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Subcutaneous LC administration resulted in a maximum plasma concentration of 26.3 to 59.78\u2009ng\/mL, time to reach maximum plasma concentration of 2 hours, area under the concentration-time curve to last measurable concentration of 669.3 to 1126\u2009h\u2009\u00d7\u2009ng\/mL, and plasma bioavailability (%F) of 19.6% to 31.3%. The PK profiles of FC after SC and IV administration differed when compared with LC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>In healthy dogs, SC LC administration at 50\u2009mg\/m2 results in measurable plasma CA concentrations, is apparently safe and well tolerated, but does not result in prolonged cytotoxic plasma concentrations. Poor absorption of LC prevented establishment of a complete LC PK profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.15809","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T15:44:04Z","timestamp":1590162244000},"page":"1563-1569","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9954-577X","authenticated-orcid":false,"given":"Irene B.","family":"Vazquez Fuster","sequence":"first","affiliation":[{"name":"VCA Hollywood Animal Hospital Department of Oncology, , Hollywood, Florida,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda R.","family":"Taylor","sequence":"additional","affiliation":[{"name":"MedVet Columbus Department of Neurology, , Worthington, Ohio,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette N.","family":"Smith","sequence":"additional","affiliation":[{"name":"Wilford and Kate Bailey Small Animal Teaching Hospital, Auburn University College of Veterinary Medicine Department of Clinical Sciences, , Auburn, Alabama,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue H.","family":"Duran","sequence":"additional","affiliation":[{"name":"J.T. Vaughan Large Animal Teaching Hospital, Auburn University College of Veterinary Medicine , Auburn, Alabama,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Ravis","sequence":"additional","affiliation":[{"name":"Harrison School of Pharmacy, Auburn University , Auburn, Alabama,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanese L.","family":"Jasper","sequence":"additional","affiliation":[{"name":"Harrison School of Pharmacy, Auburn University , Auburn, Alabama,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Harrison School of Pharmacy, Auburn University , Auburn, Alabama,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"issue":"4","key":"2026020302584369700_jvim15809-bib-0001","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1748-5827.2006.00172.x","article-title":"Combined cytosine arabinoside and prednisone therapy for meningoencephalitis of unknown aetiology in 10 dogs","volume":"47","author":"Zarfoss","year":"2006","journal-title":"J Small Anim Pract"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0002","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.tvjl.2009.03.031","article-title":"Clinical findings and treatment of non-infectious meningoencephalomyelitis in dogs: a systematic review of 457 published cases from 1962 to 2008","volume":"184","author":"Granger","year":"2010","journal-title":"Vet J"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0003","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/vr.101431","article-title":"Meningoencephalitis of unknown origin: investigation of prognostic factors and outcome using a standard treatment protocol","volume":"172","author":"Lowrie","year":"2013","journal-title":"Vet Rec"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0004","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1748-5827.2009.00823.x","article-title":"Idiopathic granulomatous and necrotising inflammatory disorders of the canine central nervous system: a review and future perspectives","volume":"51","author":"Talarico","year":"2010","journal-title":"J Small Anim Pract"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0005","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1939-1676.2006.tb00719.x","article-title":"Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma","volume":"20","author":"Alvarez","year":"2006","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0006","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1476-5829.2007.00141.x","article-title":"Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?","volume":"6","author":"Marconato","year":"2008","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0007","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.tvjl.2010.04.027","article-title":"The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects","volume":"188","author":"Marconato","year":"2011","journal-title":"Vet J"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00686329","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs","volume":"29","author":"Scott-Moncrieff","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026020302584369700_jvim15809-bib-0009","first-page":"168","article-title":"Withrow and MacEwen's Small Animal Clinical Oncology","author":"Gustafson","year":"2007","edition":"5"},{"key":"2026020302584369700_jvim15809-bib-0010","article-title":"Cancer Chemotherapy, Immunotherapy, and Biotherapy: Principles and Practice","author":"Chabner","year":"2019","edition":"6"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0011","doi-asserted-by":"crossref","first-page":"8997","DOI":"10.1016\/S0021-9258(19)70512-2","article-title":"Correlation of cytotoxicity with incorporation of ara-C into DNA","volume":"255","author":"Kufe","year":"1980","journal-title":"J Biol Chem"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0012","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/00003088-200241100-00002","article-title":"Clinical pharmacokinetics of cytarabine formulations","volume":"41","author":"Hamada","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0013","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jvp.12008","article-title":"The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes","volume":"36","author":"Crook","year":"2012","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020302584369700_jvim15809-bib-0014","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/jvp.12667","article-title":"The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology","volume":"41","author":"Pastina","year":"2018","journal-title":"J Vet Pharmacol Ther"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0015","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200645120-00002","article-title":"Pharmacology of drugs formulated with DepoFoam\u2122: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology","volume":"45","author":"Angst","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0016","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1124\/pr.115.012070","article-title":"Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come","volume":"68","author":"Yingchoncharoen","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0017","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1345\/aph.19347","article-title":"Clinical pharmacology of encapsulated sustained-release cytarabine","volume":"34","author":"Murry","year":"2000","journal-title":"Ann Pharmacother"},{"key":"2026020302584369700_jvim15809-bib-0018","first-page":"3935","article-title":"Multivesicular liposomes containing 1-\u03b2-D-arabinofuranosylcytosine for slow-release intrathecal therapy","volume":"47","author":"Kim","year":"1987","journal-title":"Cancer Res"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0019","first-page":"447","article-title":"Multivesicular liposomes containing cytarabine for slow-release Sc administration","volume":"71","author":"Kim","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"2026020302584369700_jvim15809-bib-0020","first-page":"1596","article-title":"Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam","volume":"53","author":"Kim","year":"1993","journal-title":"Cancer Res"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0021","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/vco.283","article-title":"Common terminology criteria for adverse events following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","author":"Veterinary Cooperative Oncology Group","year":"2016","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020302584369700_jvim15809-bib-0022","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.4155\/bio.11.140","article-title":"HPLC\u2013MS\/MS method for the determination of cytarabine in human plasma","volume":"3","author":"Hilhorst","year":"2011","journal-title":"Bioanalysis"},{"key":"2026020302584369700_jvim15809-bib-0023","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0378-5173(97)00135-X","article-title":"Liposomes in drug delivery: progress and limitations","volume":"154","author":"Sharma","year":"1997","journal-title":"Int J Pharm"},{"key":"2026020302584369700_jvim15809-bib-0024","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/vco.12342","article-title":"Liposome-encapsulated chemotherapy: current evidence for its use in companion animals","volume":"16","author":"B\u00f8rresen","year":"2018","journal-title":"Vet Comp Oncol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.15809","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.15809","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.15809","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/34\/4\/1563\/66660710\/jvim15809.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/34\/4\/1563\/66660710\/jvim15809.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:58:54Z","timestamp":1770105534000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/34\/4\/1563\/8448295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.15809","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"2019-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}